Senior insider sale
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. — senior position signals high conviction
$2.06M
5.98K shares
What this filing means
FITZGERALD KEVIN JOSEPH plans to sell 5.98K shares of ALNYLAM PHARMACEUTICALS, INC. valued at approximately $2.06M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 3/3/2026ACC: 0001969223-26-000276
Officer· CSO & EVP, Head of Research
Since Mar 2026
5.98K
Shares to sell
$2.06M
Approx. market value
1.65K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months2
RSU
NA
3/2/2026
805.00RSU
NA
2/27/2026
847.00Total acquired1.65K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
3/2/2026 | RSU NA | 805.00 | — |
2/27/2026 | RSU NA | 847.00 | — |
| Total | 1.65K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
2.04K
Market value
$677.5K
2/17/2026
—Completed
Units to sell
2.29K
Market value
$848.1K
1/13/2026
Planned — Approximate Date
NasdaqPlanned
Units to sell
1.65K
Market value
$530.9K
3/3/2026
Total
Units
5.98K
Value
$2.06M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
2/17/2026 | 2.04K | $677.5K | — | Completed |
1/13/2026 | 2.29K | $848.1K | — | Completed |
| Planned — Approximate Date | ||||
3/3/2026 | 1.65K | $530.9K | Nasdaq | Planned |
| Total | 5.98K | $2.06M | ||